Acrivon Therapeutics宣布其靶向药物Acr-368在二期B组子宫内膜癌临床试验中取得积极结果。为加速患者招募进程，公司同步启动欧盟地区临床扩展计划。本次公告同时首次披露了双特异性候选药物Acr-2316的初步临床数据，并正式推出基于AP3精准蛋白组学平台开发的下一代候选药物Acr-6840，该药物主要靶向细胞周期关键调控因子Cdk11蛋白。
通过AP3平台技术，Acrivon实现了对药物敏感生物标志物的精准识别，为临床试验分层提供科学依据。最新数据显示，Acr-368在经生物标志物筛选的子宫内膜癌患者群体中展现出显著临床活性，具体疗效指标将于后续医学会议公布。欧盟扩展计划将覆盖德国、法国等主要医疗市场，预计将大幅缩短临床试验周期。
首次亮相的Acr-2316作为双特异性靶向疗法，初步临床数据证实其良好安全性与药理特性。而新候选药物Acr-6840的推出，标志着公司基于AP3平台研发管线的进一步拓展，该药物通过靶向Cdk11调控肿瘤细胞周期进程，为难治性肿瘤患者提供新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.